Table 1 Neutralization sensitivity (IC50) of BaL (tier 1), JR-FL (tier 2), and C34r mutants by purified IgG from HIV-1 infected patients
From: Enhanced antibody-mediated neutralization of HIV-1 variants that are resistant to fusion inhibitors
Patient ID | IC50 (µg/mL) | ||
|---|---|---|---|
BaL | JR-FL | C34r | |
Patient 1 | 27 | >300 | >300 |
Patient 2 | 119 | >300 | 74 |
Patient 3 | 114 | >300 | 190 |
Patient 4 | 46 | 240 | 61 |
Patient 5 | 124 | >300 | >300 |
Patient 6 | >300 | >300 | >300 |
Patient 7 | 178 | >300 | 8.4 |
Patient 8 | 11 | 30 | 48 |
Patient 9 | 6 | 66 | 46 |
Patient 10 | 18 | >300 | 161 |
KTS376 | 9 | 45 | 70 |
Total neutralized | 91 % | 36 % | 73 % |